127 related articles for article (PubMed ID: 33400304)
1. Transcriptome modulation following administration of luteolin to bleomycin-etoposide-cisplatin chemotherapy on rat LC540 tumor Leydig cells.
Nguyen HT; Couture R; Touaibia M; Martin LJ
Andrologia; 2021 Mar; 53(2):e13960. PubMed ID: 33400304
[TBL] [Abstract][Full Text] [Related]
2. Effects of bleomycin, etoposide and cisplatin treatment on Leydig cell structure and transcription of steroidogenic enzymes in rat testis.
Al-Bader M; Kilarkaje N
Eur J Pharmacol; 2015 Jan; 747():150-9. PubMed ID: 25523482
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Changes in Serum Levels of Testosterone and Luteinizing Hormone in Testicular Cancer Patients after Orchiectomy Alone or Bleomycin, Etoposide, and Cisplatin.
Bandak M; Jørgensen N; Juul A; Lauritsen J; Kier MGG; Mortensen MS; Daugaard G
Eur Urol Focus; 2018 Jul; 4(4):591-598. PubMed ID: 28753832
[TBL] [Abstract][Full Text] [Related]
4. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
5. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of sodium alginate on bleomycin, etoposide and cisplatin (BEP)-induced reproductive toxicity by inhibiting nitro-oxidative stress, inflammation and apoptosis.
Moradi M; Hashemian MA; Faramarzi A; Goodarzi N; Hashemian AH; Cheraghi H; Jalili C
Sci Rep; 2024 Jan; 14(1):1565. PubMed ID: 38238398
[TBL] [Abstract][Full Text] [Related]
7. Impact of the chemotherapy cocktail used to treat testicular cancer on the gene expression profile of germ cells from male Brown-Norway rats.
Delbès G; Chan D; Pakarinen P; Trasler JM; Hales BF; Robaire B
Biol Reprod; 2009 Feb; 80(2):320-7. PubMed ID: 18987330
[TBL] [Abstract][Full Text] [Related]
8. Improvement of Rat Sperm Chromatin Integrity and Spermatogenesis with Omega 3 following Bleomycin, Etoposide and Cisplatin Treatment.
Razavi S; Hashemi F; Khadivi F; Bakhtiari A; Mokhtarian A; Mirzaei H
Nutr Cancer; 2021; 73(3):514-522. PubMed ID: 32321280
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.
Dearnaley DP; Horwich A; A'Hern R; Nicholls J; Jay G; Hendry WF; Peckham MJ
Eur J Cancer; 1991; 27(6):684-91. PubMed ID: 1712606
[TBL] [Abstract][Full Text] [Related]
10. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.
Horwich A; Sleijfer DT; Fosså SD; Kaye SB; Oliver RT; Cullen MH; Mead GM; de Wit R; de Mulder PH; Dearnaley DP; Cook PA; Sylvester RJ; Stenning SP
J Clin Oncol; 1997 May; 15(5):1844-52. PubMed ID: 9164194
[TBL] [Abstract][Full Text] [Related]
12. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
13. Luteolin modulates gene expression related to steroidogenesis, apoptosis, and stress response in rat LC540 tumor Leydig cells.
Couture R; Mora N; Al Bittar S; Najih M; Touaibia M; Martin LJ
Cell Biol Toxicol; 2020 Feb; 36(1):31-49. PubMed ID: 31201582
[TBL] [Abstract][Full Text] [Related]
14. Physical exercise in patients with testicular cancer treated with bleomycin, etoposide and cisplatin chemotherapy: pulmonary and vascular endothelial function-an exploratory analysis.
van der Schoot GGF; Ormel HL; Westerink NL; Wempe JB; Lefrandt JD; May AM; Vrieling AH; Meijer C; Gietema JA; Walenkamp AME
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17467-17478. PubMed ID: 37889308
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.
Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP;
J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).
Cafferty FH; White JD; Shamash J; Hennig I; Stenning SP; Huddart RA;
Eur J Cancer; 2020 Mar; 127():139-149. PubMed ID: 32007714
[TBL] [Abstract][Full Text] [Related]
17. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
de Wit R; Stoter G; Sleijfer DT; Neijt JP; ten Bokkel Huinink WW; de Prijck L; Collette L; Sylvester R
Br J Cancer; 1998 Sep; 78(6):828-32. PubMed ID: 9743309
[TBL] [Abstract][Full Text] [Related]
18. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.
de Wit R; Stoter G; Kaye SB; Sleijfer DT; Jones WG; ten Bokkel Huinink WW; Rea LA; Collette L; Sylvester R
J Clin Oncol; 1997 May; 15(5):1837-43. PubMed ID: 9164193
[TBL] [Abstract][Full Text] [Related]
19. Selective induction of glutathione S-transferases in round spermatids from the Brown-Norway rat by the chemotherapeutic regimen for testicular cancer.
Delbès G; Chan D; Hales BF; Trasler JM; Robaire B
Reprod Toxicol; 2013 Apr; 36():24-32. PubMed ID: 23200778
[TBL] [Abstract][Full Text] [Related]
20. Reversibility of the effects of subchronic exposure to the cancer chemotherapeutics bleomycin, etoposide, and cisplatin on spermatogenesis, fertility, and progeny outcome in the male rat.
Marcon L; Hales BF; Robaire B
J Androl; 2008; 29(4):408-17. PubMed ID: 18296477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
